

## **Medegen Prevails on Appeal in ICU Medical Inc. Patent Infringement Case**

### **Leader in infusion therapy medical products protects proprietary innovation**

Ontario, CA (December 2, 2008) – Medegen <<http://medegen.com/>> , a leading innovator in infusion therapy medical products, announced today that it has won an important legal victory in the United States Court of Appeals for the Federal Circuit in Washington, D.C. The appellate court's decision reverses a judgment issued by a district court judge in the Central District of California of patent non-infringement entered in favor of ICU Medical Inc. (NASDAQ: ICUI).

Medegen argued successfully that the decision below inappropriately narrowed the definition of key terms of one of its patents (U.S. Patent No. 5,730,418). This patent covers a number of Medegen's novel inventions in needleless connectors, including the use of positive displacement technology, which reduces the occurrence of common vascular access device-related complications. The case is now returned to the lower court with the appellate court having interpreted key claim language as Medegen had requested.

"Medegen's intellectual property is valuable and we feel strongly about protecting our innovations. We are encouraged by the successful outcome of our appeal," said Jeffrey Goble, President of Medegen.

### **About Medegen Inc.**

Medegen is a leading innovator in infusion therapy, focused on helping hospitals drive greater clinical performance for improved patient care. The growing company provides clinically superior medical products and reliable, cost-effective manufacturing services to the medical community through its three operating units: Manufacturing Services, Maximus and KippMed. Manufacturing Services provides cost-effective contract manufacturing solutions to medical device, drug delivery and pharmaceutical companies. KippMed manufactures and markets IV therapy components for the OEM market, drawing from a 25-year history in IV component supply. Maximus develops, manufactures and markets needleless intravenous therapy products for the acute care market. The Maximus line of medical products features patent-protected technologies which improve patient outcomes and greatly reduce bloodstream infection rates. Medegen is headquartered in Ontario, Calif. with executive offices in Scottsdale, Ariz. and operations in Tijuana, Mexico. For more visit <http://www.medegen.com/>.